Alkermes registers Phase 2 trial of ALKS 7290 for adult ADHD

Alkermes had one registry update this week, a newly posted Phase 2 trial for its investigational ADHD drug ALKS 7290.

• ALKS 7290-201 is a Phase 2, randomized, parallel-group, double-blind study comparing ALKS 7290 tablets to placebo in adults with attention deficit hyperactivity disorder, sponsored by Alkermes, Inc.¹ The trial's status is recruiting, with an estimated enrollment of 312 participants¹ and a primary endpoint of change from baseline to Week 4 in the Attention Deficit Disorder Investigator Symptom Rating Scale total score¹. The study is running at two sites in the United States, in Chino, California and Maitland, Florida¹.